Been there, done that ... what's next?

Home
Hep C Kick Start
Hep C Transmission
CHRONIC Hep C
Fight Brain Fog
Straightup Q n A
To Treat or Not ...
Dragon Slayers
What's Next?
Hep C in the News
In Memoriam
Straightup News
Links Straightup
Events & Swaps
Get Straightup Updates
Spread the word
Guestbook
Donate
Kudos
About the Straightup
Straightup Legal stuff
Our Privacy Policy

Been There, Done That

There's a lot of us who've tried the whole treatment thing.  It didn't work; either because:

  • we're in the "lucky" 75% of U.S. genotype 1's, half of whom don't clear the virus 6 months post treatment, or
  • we developed an allergy or rash or autoimmune disease or some other such crap from the medicine, or
  • were about to lose our job, thus our insurance, or
  • we just couldn't f-ing take it anymore, or
  • because we didn't want to - or couldn't - stop drinking,
  • or ________________________ (fill in the blank).

o.k., o.k. ... that's enough whining.  Here's what's coming down the pike.


Inhibitors

           (and we don't mean shy people)

As you may recall from the straightup on why hep C's so hard to get rid of (here), the virus gets inside of us and reproduces itself - a lot like our normal proteins & enzymes inside of us do, except we want to keep the good stuff .  Get the picture?  If not take a look at this flash movie for a minute ... here.i dunno Marge - maybe it needs a little more salt....

So the next thing scientists and pharmaceutical companies are working on are inhibitors (protease, polymerase and caspase inhibitors).  If they sound like the drugs people with HIV take to keep from getting AIDS - it's because they are ... except targeted for hep C.

Anyway ... what these will do is make the virus stop reproducing itself, to give the interferon a chance to do its stuff.  It's hoped that the inhibitors will cut out the whole ribavirin part and shorten the time on treatment.  So we get less sick, more genotype 1's get cured and insurance companies and the rest of us are happy.

The catch ...

 ... to find an inhibitor that won't stop the good proteins and enzymes to stop replicating, thereby causing organ failure.  It's pretty tricky - and something to be careful about jumping into until these drugs get to Phase III or IV trials.

So, of the several possible new inhibitors found (aka, drug candidates, or novel compounds), most don't get out of pre-clinical studies - the monkey died.  At this point, these baby drugs are referred to by initials & numbers.  If they show promise, a company will give the thing a name.  Hep C Straightup will do our best to track these for ya in the tables below. 


 

 

 

Note: we took out the table for Baby Drugs with no name, as there's just too damn many to keep track of.  This is only a good thing for us, tho.  The ones that may show promise for us sooner are on the table below.

 

 

 

 

Baby Drugs with Names, still in the running ... 

Drug Name

Drug Type

Drug Company

Phase

What Science Has
Proven
(or not) - So Far

Actilon

fka 

CPG-0101

Immune booster

Coley Pharmaceutical Group

Ib

Hep C virus declined WITHIN 24 HOURS for the group that took the highest dose. Enrollment's closed for Phase Ib, which will be done by January 2007.

Albuferon

Immuno-modulator

Human Genome Sciences

III

Albuferon is kind of like a souped-up interferon. This small company is sinking tons of effort into its success, & passed their phase II Quality of Life (QoL) study. Phase III studies will feature two studies: one for genotype 1's and one for genotypes 2 & 3.

Bavituxomab

monoclonal antibody antiviral

Peregrine Pharmaceuticals

II

Pre-clinical ended early. So far … the monkey didn't die. Enrollment for Phase I is closed a little ahead of schedule, per company press release, 10/24/06. Guess they're pretty excited about that.

Merimepodib

fka

VX-497

??

Vertex Pharmaceuticals, Johnson & Johnson

II

At the end of a 24-week treatment with triple therapy: Merimepodib, Pegasys & Copegus, 86% of participants went viral negative. 

Suvus

??

Bioenvision, Inc.

II

Reduced viral load in hep C patients- many with cirrhosis.  Press Release was pretty vague, though.  Not much detail.  Data will be presented Sept. 7-8, 2006 in Dublin, Ireland.

Telapravir     fka VX-950

protease inhibitor

Vertex Pharmaceuticals, Johnson & Johnson

II

Data from several studies (PROVE 1) of this drug were just released, per company press release 10/27/2006. Findings are kind of a mixed bag, but still pretty good. In another, people who got the inhibitor + peg inf + riba (Roche's) stayed viral negative 12 wks POST TREATMENT; not so for the ones who did only the Telapravir. A couple people quit & no one's saying why. All the patients are genotype 1, hard-to-treat. Clinics are currently enrolling for PROVE 2, to be completed by year-end.

Valopicitabine

fka 

NM283

polymerase inhibitor

Idenix Pharmaceuticals

II

In this large-scale trial some folks got NM283 alone, others got it with Peg-inf/riba. 72% of the people who did the combination cleared at 12 weeks, yet opted to continue the peg/riba for the full 48 weeks.

Viramidine

Pro-drug of Ribavirin (meaning, same drug, different name)

Valeant Pharmaceuticals (FKA Ribapharm)

II

Valeant's phase II study didn't get people to go SVR negative (38%, vs. 52%, regular riba). Valeant said this had to do with weight-based dosing. Returning once again from the drawing board, they have a high-dose phase IIb in the pipeline. Straight up ... this one's outta there. The SEC's even investigating company top dogs for selling stock, per company press release 9/13/2006

These tables are updated as soon as we hear, and have an internet connection.  The information provided comes from primary & secondary sources, such as Principal Investigators of the studies, or their staff, but mostly from press releases.  For the bottom line on your decisions, see our disclaimer ... here.

       fyi ...

 

like shovelheads and science, these drugs are a work in progress.

                                                                                                                Stay tuned ....

New Hep C Treatments

(maybe)

in the News... here

The FDA
   … aka Food & Drug Administration is the agency that gives drug companies the go ahead - or not - to sell medications in the U.S.

   Ideally, the drugs have to pass a series of studies, aka Phases.  FDA.gov's site describes them like so:

Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects

Phase II: The study drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

Phase III: The study drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

   Straightup, the best deal for us is the Phase IV trial, aka "marketing study" that will determine what kind of language a Pharma can use to sell its drug.  Our best bet because the drug's already proven safe.

   There's also "Pre-clinical," which is pretty much lab stuff; messing with gunk in petri dishes; animal testing ... like with hep C, chimpanzees are used, because dogs can't catch it; preclinical proves the general concept.


Hey ... I'm not a doctor - don't even play one on t.v. - so, check out my little disclaimer ... here.

on: 03.15.2008

We're damn proud to tell ya that
We comply with the HONcode standard for health trust worthy information:
verify here.

website by Nerd Grrl Design

questions? comments?                                                                             Hep C Straightup respects your right to privacy

please click on the webmaster (also a hepper, by the way)      what's the deal, pickle?  

Hep C Straightup - Copyright Ó 2008.  All Rights Reserved.